{
    "id": 2139,
    "fullName": "PTEN negative",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "PTEN negative indicates a lack of the PTEN gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5728,
        "geneSymbol": "PTEN",
        "terms": [
            "PTEN",
            "10q23del",
            "BZS",
            "CWS1",
            "DEC",
            "GLM2",
            "MHAM",
            "MMAC1",
            "PTEN1",
            "PTENbeta",
            "TEP1"
        ]
    },
    "variant": "negative",
    "createDate": "10/09/2014",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20723,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, negative PTEN IHC staining were detected more frequently in patients with renal cell carcinoma who responded to treatment with Afinitor (everolimus) or Torisel (temsirolimus) (odds ratio = 0.24, p=0.029) than those who did not respond (PMID: 31335987).",
            "molecularProfile": {
                "id": 2077,
                "profileName": "PTEN negative"
            },
            "therapy": {
                "id": 936,
                "therapyName": "Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18013,
                    "pubMedId": 31335987,
                    "title": "PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31335987"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9816,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, one patient with Pten negative squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748).",
            "molecularProfile": {
                "id": 2077,
                "profileName": "PTEN negative"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7642,
                    "pubMedId": 26098748,
                    "title": "Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26098748"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1180,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PTEN-deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, Talazoparib (BMN-673) (PMID: 23881923).",
            "molecularProfile": {
                "id": 2077,
                "profileName": "PTEN negative"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 520,
                    "pubMedId": 23881923,
                    "title": "BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23881923"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20724,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, negative PTEN IHC staining were detected more frequently in patients with renal cell carcinoma who responded to treatment with Afinitor (everolimus) or Torisel (temsirolimus) (odds ratio = 0.24, p=0.029) than those who did not respond (PMID: 31335987).",
            "molecularProfile": {
                "id": 2077,
                "profileName": "PTEN negative"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18013,
                    "pubMedId": 31335987,
                    "title": "PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31335987"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20804,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, negative PTEN IHC staining was not associated with response to Zejula (niraparib) treatment in patients with castration-resistant prostate cancer (PMID: 23810788; NCT00749502).",
            "molecularProfile": {
                "id": 2077,
                "profileName": "PTEN negative"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "not predictive",
            "references": [
                {
                    "id": 1986,
                    "pubMedId": 23810788,
                    "title": "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23810788"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3240,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Caprelsa (vandetinib), in combination with radiation therapy and Temodar (temozolomide), demonstrated no difference in PFS and OS when compared between glioblastoma patients negative for PTEN versus those positive for PTEN (PMID: 25910950).",
            "molecularProfile": {
                "id": 2077,
                "profileName": "PTEN negative"
            },
            "therapy": {
                "id": 3094,
                "therapyName": "Temozolomide + Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3688,
                    "pubMedId": 25910950,
                    "title": "A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25910950"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 8168,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152).",
            "molecularProfile": {
                "id": 26183,
                "profileName": "BRAF V600X PTEN neg"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6551,
                    "pubMedId": 24265152,
                    "title": "A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17667,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic ovarian cancer lacking PTEN expression did not respond to treatment with Ibrance (palbociclib), and was found to harbor RB1 R522* and CDK4 E184K, which potentially contributed to the lack of response (PMID: 31145688).",
            "molecularProfile": {
                "id": 32736,
                "profileName": "CDK4 E184K PTEN neg RB1 R552*"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15724,
                    "pubMedId": 31145688,
                    "title": "Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31145688"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20728,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, negative PTEN IHC staining combined with MTOR mutations was associated with better response to treatment with Afinitor (everolimus) or Torisel (temsirolimus) (odds ratio = 0.16, p=0.008) in patients with renal cell carcinoma (PMID: 31335987).",
            "molecularProfile": {
                "id": 35310,
                "profileName": "MTOR mut PTEN neg"
            },
            "therapy": {
                "id": 936,
                "therapyName": "Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18013,
                    "pubMedId": 31335987,
                    "title": "PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31335987"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20729,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, negative PTEN IHC staining combined with MTOR mutations was associated with better response to treatment with Afinitor (everolimus) or Torisel (temsirolimus) (odds ratio = 0.16, p=0.008) in patients with renal cell carcinoma (PMID: 31335987).",
            "molecularProfile": {
                "id": 35310,
                "profileName": "MTOR mut PTEN neg"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18013,
                    "pubMedId": 31335987,
                    "title": "PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31335987"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2077,
            "profileName": "PTEN negative",
            "profileTreatmentApproaches": [
                {
                    "id": 12435,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PTEN negative"
                },
                {
                    "id": 12437,
                    "name": "PIK3CB inhibitor",
                    "profileName": "PTEN negative"
                },
                {
                    "id": 12436,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PTEN negative"
                },
                {
                    "id": 12434,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PTEN negative"
                },
                {
                    "id": 12433,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PTEN negative"
                }
            ]
        },
        {
            "id": 26183,
            "profileName": "BRAF V600X PTEN neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32707,
            "profileName": "PTEN neg RB1 R255*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32736,
            "profileName": "CDK4 E184K PTEN neg RB1 R552*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35310,
            "profileName": "MTOR mut PTEN neg",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}